Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Medication Guides: Patient Medication Information Proposed Rule.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Postmarketing Approaches to Obtain Data on Under-Represented Populations in Clinical Trials Draft Guidance for Industry.

Representation is important to cancer patients and survivors when it comes to the composition of clinical trials, with patients saying it is important that drugs are tested among patients who share their gender, age, and general health. Women consider it more important that drugs be tested in patients who share their gender than do men, while people of color are most concerned about representation in clinical trials.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) Draft Guidance on Decentralized Clinical Trials. 

These consensus recommendations endorsed by 12 organizations identify key steps to improve equitable pharmacogenomic (PGx) discovery and  implementation.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Pharmacogenomic Data Submissions Draft Guidance for Industry. 

By focusing explicitly on bold, transformative, and applied research projects, ARPA-H holds the potential to quickly bridge the gap between the research lab and the patient. 

To ensure that the research being supported today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing.

ACS CAN was joined by 22 other organizations in proposing the HHS Office of Inspector General (OIG) adopt a new regulatory safe harbor from the Anti-kickback Statute (AKS) that would allow clinical trial sponsors to financially support patients to offset extra non-medical costs associated with cl